D. E. Shaw & Co., Inc. 89bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.13 - $13.77 $337,687 - $571,950	41,536 Added 297.6%	55,493 $645,000
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $28,957 - $69,698	-4,348 Reduced 23.75%	13,957 $155,000
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $5.89 Million - $7.59 Million	-390,941 Reduced 95.53%	18,305 $282,000
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $3.58 Million - $5.57 Million	252,743 Added 161.49%	409,246 $7.76 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $1.64 Million - $2.65 Million	156,503 New	156,503 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $58,787 - $113,074	28,128 Added 42.68%	94,036 $303,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $227,382 - $987,960	65,908 New	65,908 $248,000

157

107M

65K

1.2M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $334M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.